CLPT · CIK 0001285550
What ClearPoint Neuro, Inc. told the SEC could break it.
ClearPoint Neuro's disclosures describe concentration at nearly every point of its business. On demand, it leans on a few customers with almost no committed-volume contracts — its five largest hospital customers were about 21% of neurosurgery disposable revenue, and one partner, PTC Therapeutics, was roughly 15% of its biologics and drug-delivery revenue. On supply, it depends on single-source suppliers for key products: CLS is the sole supplier of its Prism Neuro laser system (and itself relies on single sources), and its IRRA flow catheters and disposables come from single-source suppliers without fully qualified alternatives. Adding to the fragility, it runs most R&D, assembly, packaging and distribution from a single Southern California site — in an earthquake- and wildfire-prone region — with no redundant facilities, all under extensive FDA device regulation.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- customer concentration — five largest hospital customers ~21% of neurosurgery disposable revenue; PTC Therapeutics ~15% of biologics & drug-delivery revenue; almost no long-term committed-volume contractshigh
ClearPoint Neuro depends on a small number of customers: its five largest hospital customers accounted for approximately 21% of its neurosurgery navigation disposable product revenues in 2025, and within biologics & drug delivery one partner — PTC Therapeutics — represented about 15% of that segment's revenue; because revenues from almost all customers are not based on long-term, committed volume purchase contracts, the loss of, or reduced purchasing by, a major hospital or PTC could cause its revenues to fluctuate significantly.
“Our five largest hospital customers accounted for approximately 21% of our neurosurgery navigation disposable product revenues in 2025.”
SEC filing →As of 2026
Sole-source dependency
- single-source supplier dependence — CLS is the sole supplier of the ClearPoint Prism Neuro Laser Therapy System (and CLS itself relies on single-source suppliers); IRRA flow catheters/disposables sourced from single-source suppliers without fully qualified alternativeshigh
ClearPoint relies on single-source suppliers for key products: the ClearPoint Prism Neuro Laser Therapy System is manufactured exclusively by and supplied by CLS (a single-source supplier that itself depends on single-source suppliers for components/subassemblies), and it sources the catheters and procedure-specific disposables for its IRRA flow system from single-source suppliers, without currently maintaining multiple qualified suppliers for all of these products; a disruption at CLS or these single-source suppliers could interrupt product availability and materially harm its business.
“The ClearPoint Prism Neuro Laser Therapy System is supplied to us by CLS, and we rely on CLS as a single-source supplier for this product.”
SEC filing →As of 2026
Geographic concentration
- single-region operations — most R&D, processing, assembly, packaging and distribution at Southern California facilities (Solana Beach/San Diego) with no redundant facilities; earthquake/wildfire exposuremedium
ClearPoint conducts many of its activities — research and development, component processing, final assembly, packaging and distribution for most products — at facilities in Southern California (Solana Beach/San Diego) and does not have redundant facilities; Southern California is a seismically active area that has experienced major earthquakes and is prone to wildfires, so an earthquake, wildfire, pandemic, cyberattack or other catastrophe at these single-region sites could halt manufacturing and distribution and materially disrupt its business.
“We conduct many of our activities, including research and development, component processing, final assembly, packaging and distribution activities for most of our products, at our facilities located in Southern California, which is a seismically active area that has experienced major earthquakes in the past, as well as other natural disasters, including wildfires.”
Regulatory & policy
- FDA/medical-device regulation — Quality Management System Regulation (QMSR) compliance for the company and its third-party suppliers, off-label-promotion liability, device clearances (EU MDR, international), and third-party (Medicare/Medicaid/private) reimbursement dependencelow
ClearPoint is subject to extensive medical-device regulation: if it or its third-party suppliers fail to comply with the FDA's Quality Management System Regulation (QMSR) or state equivalents, its manufacturing could be interrupted; it also faces off-label-promotion liability, must obtain and maintain device clearances/approvals (e.g., EU MDR certification and clearances across 34 countries), and its sales depend in part on third-party payors (Medicare, Medicaid and private payers) covering and reimbursing procedures using its devices — so regulatory or reimbursement setbacks could materially reduce demand and disrupt operations.
“If we or our third-party suppliers fail to comply with the FDA's Quality Management System Regulation (“QMSR”) or any applicable state equivalent, our manufacturing operations could be interrupted, and our potential product sales and operating results could suffer.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“One of these companies, PTC Therapeutics, Inc. and its affiliates (“PTC”), accounted for approximately 15% of our biologics and drug delivery revenues in 2025. One of our directors is PTC's Chief Executive Officer and President. In May 2019, we entered into a supply agreement with PTC (the “PTC Supply Agreement”) pursuant to which we supply certain products and engage in p”
Cited →
Its suppliers
CLS (Clinical Laserthermia Systems)
“The ClearPoint Prism Neuro Laser Therapy System is supplied to us by CLS, and we rely on CLS as a single-source supplier for this product. CLS may itself rely on single source suppliers for certain components, subassemblies, or materials used in the manufacture of the ClearPoint Prism Neuro Laser Therapy System.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch